Glox Therapeutics Appoints Dr. Michael Murray as Chair and Dr. Nel Moore to Scientific Advisory Board
Glox Therapeutics, a leader in developing precision antibiotic therapies using naturally occurring bacteriocins, has announced the appointment of Dr. Michael Murray as Chair of the Board. Dr. Murray will collaborate with the team to drive the company’s growth and support the commercialization of its groundbreaking technology. Additionally, Glox has expanded its Scientific Advisory Board (SAB) by adding Dr. Nel Moore. Dr. Moore will provide expertise to advance the company’s novel engineered protein bacteriocins, designed to target drug-resistant pathogenic bacteria and address the growing issue of antimicrobial resistance (AMR).
Glox Therapeutics, a pioneering company in the development of precision antibiotics using naturally occurring bacteriocins, has announced the appointment of Dr. Michael Murray as Chair of the Board and Dr. Nel Moore to its Scientific Advisory Board (SAB). These appointments will strengthen the company’s leadership team as it continues to advance its mission to combat antimicrobial resistance (AMR) through the development of novel, engineered protein bacteriocins.
Dr. Michael Murray: Extensive Leadership Experience
Dr. Michael Murray brings almost three decades of expertise in the life sciences sector. He is the Principal at Murray International Partners and has led high-value international deals in biotechnology and pharmaceuticals, offering his expertise in intellectual property management, market assessment, and deal-making to support a range of organizations from startups to multinational corporations. Dr. Murray has held senior management roles at several biotech and pharma companies, including Metallobio, Porton Biopharma, EnteroBiotix, Sosei Heptares, and Amura Therapeutics. His work spans the realms of commercial strategy, intellectual property, and business development
Dr. Murray is also an educator, teaching commercial intellectual property strategy in the Novo Nordisk Fellowship MBA in Biomedical Design program in Denmark. He has provided training to over 1,200 individuals in commercializing technical innovations since 2015.
Additionally, Dr. Murray is a Member of The Royal Society Industry College and an Entrepreneur in Residence at the University of Sheffield, where he served as a Royal Society Entrepreneur in Residence from 2019–2022. He also holds the position of Mentor at Cambridge Enterprise and has contributed to several advisory boards and committees, including Coeliac UK. Dr. Murray is a Registered Technology Transfer Professional and a Member of the International Technology Transfer Network in China. He holds a PhD in Molecular Cell Biology from the University of Leicester.
Dr. Nel Moore: Expertise in Drug Discovery and Development
Dr. Nel Moore brings significant experience in drug discovery, development, and commercialization, particularly in the areas of immunology, oncology, and anti-infectives. Over the course of her 21-year career in the pharmaceutical industry, Dr. Moore has held senior roles, including Vice President of Antibiotics Development at AstraZeneca. There, she led the late-stage development, regulatory submission, and approval of Zavicefta™/Avycaz™ for multidrug-resistant bacterial infections. Dr. Moore further strengthened AstraZeneca’s antibiotics development division, supporting multiple antibiotics in various stages of development and commercialization before the division was divested to Pfizer.
Since 2018, Dr. Moore has been advising biotech companies in strategic planning, business development, and fundraising through her role as a senior R&D consultant at FWEast. She also serves as Executive Chair/CEO of CHAIN Biotechnology and holds an Independent Council Member role at Aston University. Additionally, she is involved in multiple CARB-X Advisory Boards. Dr. Moore holds a PhD in Biochemistry from the University of Birmingham.
Expanding the Scientific Advisory Board
Dr. Moore joins an esteemed group of experts on Glox Therapeutics’ SAB, which is led by Prof. Christoph Tang FMedSci, Professor of Cellular Pathology at the University of Oxford. Other distinguished members of the SAB include Prof. Colin Kleanthous FMedSci, co-founder of Glox Therapeutics and Professor of Microbial Biochemistry at the University of Oxford; Prof. Derrick Crook, Consultant Physician in Infectious Diseases at Oxford University Hospitals NHS Foundation Trust; Dr. Michael Steward, a biopharmaceutical drug discovery scientist with over 25 years of experience; and Prof. Gerhard Winter, Chair of Pharmaceutical Technology and Biopharmacy at Ludwig Maximilian University of Munich.
Glox Therapeutics’ Future Plans and Goals
Dr. James Clark, CEO and Co-founder of Glox Therapeutics, expressed excitement about the new appointments, stating, “Drs. Murray and Moore have an outstanding track record in their respective fields. We are delighted to welcome both of these eminent individuals on board as we continue to drive expansion and strengthen our team. Their commercial expertise and unique research perspectives will be an invaluable strategic resource as we strive toward our goal of creating potent, species-specific antibiotics that combat AMR.”
Dr. Michael Murray, the newly appointed Chair, commented on his role at Glox Therapeutics, saying, “It’s a thrilling time to be joining the Board following the company’s successful seed funding round and PACE and CF AMR Syndicate grants. The exemplary team at Glox Therapeutics and the caliber of science behind its pioneering platform are set to transform the management of AMR infections. I’m excited to help the company grow and continue to progress its therapeutic program to unlock the incredible potential of this technology.”
Dr. Nel Moore, in her new role as SAB member, expressed enthusiasm about Glox Therapeutics’ innovative approach to antibiotic development. “Glox Therapeutics’ engineered protein bacteriocins represent an entirely new class of therapeutic antibiotics to target pathogenic bacteria related to AMR, helping to address the current shortcomings in this field. I very much look forward to working closely with their highly accomplished team to prevent and treat bacterial infections that pose a major threat to global human health.”
